TG Therapeutics, Inc.
IT ˙ BIT ˙ US88322Q1085
34,00 € 0,00 (0,00%)
2026-06-03
DEL PRIS
SecurityIT:1TGTX / TG Therapeutics, Inc.
InstitutionXponance, Inc.
Latest Disclosed Ownership13,679 shares
Latest Disclosed Value $ 454,416
Xponance, Inc. reports 18.76% increase in ownership of 1TGTX / TG Therapeutics, Inc.

On May 13, 2026 - Xponance, Inc. filed a 13F-HR form disclosing ownership of 13,679 shares of TG Therapeutics, Inc. (IT:1TGTX) valued at $378,361 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 11,518 shares of TG Therapeutics, Inc.. This represents a change in shares of 18.76% during the quarter. The current value of the position is $465,086 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F TG THERAPEUTICS COM 88322Q108 13,679 2,161 18.76 454 32.36 0.0032
2026-02-12 2025-12-31 13F TG THERAPEUTICS COM 88322Q108 11,518 99 0.87 343 -16.75 0.0026
2025-11-12 2025-09-30 13F TG THERAPEUTICS COM 88322Q108 11,419 74 0.65 413 0.98 0.0033
2025-08-14 2025-06-30 13F TG THERAPEUTICS COM 88322Q108 11,345 484 4.46 408 -4.67 0.0034
2025-05-01 2025-03-31 13F TG THERAPEUTICS COM 88322Q108 10,861 543 5.26 428 38.06 0.0041
2025-02-11 2024-12-31 13F TG THERAPEUTICS COM 88322Q108 10,318 1,326 14.75 311 47.62 0.0028
2024-11-12 2024-09-30 13F TG THERAPEUTICS COM 88322Q108 8,992 8,992 210 0.0020
2022-01-31 2021-12-31 13F TG THERAPEUTICS COM 88322Q108 0 -6,021 -100.00 0 -100.00
2021-11-05 2021-09-30 13F TG THERAPEUTICS COM 88322Q108 6,021 -997 -14.21 200 -26.47 0.0038
2021-08-12 2021-06-30 13F TG THERAPEUTICS COM 88322Q108 7,018 7,018 272 0.0050
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.